BIO 2024German Exhibitors Mallia Therapeutics GmbH
Mallia Therapeutics GmbH
Booth number: 4315-10
www.mallia-therapeutics.com
About us
Mallia Therapeutics GmbH is a biopharmaceutical company focused on developing novel treatments for patients suffering from hair loss. Hormone-induced male or female pattern hair loss (androgenetic alopecia) affects over half of all men and many women. Mallia Therapeutics aims to enter the multi-billion-dollar alopecia market by offering patients a safe and effective topical therapy based on the human soluble protein sCD83. Promising preclinical data show that the immunomodulator sCD83 stimulates both hair growth and new hair follicle formation via a dual mechanism of action with no evidence of the side effects common for systemic treatments. Thus, sCD83 should offer distinct advantages over marketed treatments. The Company is led by an experienced management team and worldwide leading experts in the field of CD83 biology.
Address
Mallia Therapeutics GmbH
Henkestr. 91
91052 Erlangen
Germany
Phone: +49 176 17007915
Henkestr. 91
91052 Erlangen
Germany
Phone: +49 176 17007915
Contact person:
Dr. Manfred Groeppel
General Manager
E-mail: groeppel@mallia-therapeutics.com
Phone: +49 176 17007915
Products & Services
Biotechnology
sCD83
sCD83 is an immune-modulatory protein that can induce new hair growth when applied topically. In preclinical in vivo models, it activates hair follicles via regulatory T cells. In addition, sCD83 directly binds to hair follicles to activate hair follicle stem cells and thus inducing new hair growth.
